J2353 HCPCS Level II code: Injection, octreotide, depot form for intramuscular injection, 1 mg
J2353 is the HCPCS code for “Injection, octreotide, depot form for intramuscular injection, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J2353Injection, octreotide, depot form for intramuscular injection, 1 mg
Short description: Octreotide injection, depot
HCPCS · United States
Medicare details
The indicators CMS publishes with J2353 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2004
Where J2353 sits
- 1J codesDrugs administered other than orally
- 2Active code J2353Injection, octreotide, depot form for intramuscular injection, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J2353 mean?
J2353 is the HCPCS code for “Injection, octreotide, depot form for intramuscular injection, 1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J2353?
CMS lists J2353’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J2353
All J codesJ2325Injection, nesiritide, 0.1 mgJ2326Injection, nusinersen, 0.1 mgJ2327Injection, risankizumab-rzaa, intravenous, 1 mgJ2329Injection, ublituximab-xiiy, 1mgJ2350Injection, ocrelizumab, 1 mgJ2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsqJ2354Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcgJ2355Injection, oprelvekin, 5 mgJ2356Injection, tezepelumab-ekko, 1 mgJ2357Injection, omalizumab, 5 mgJ2358Injection, olanzapine, long-acting, 1 mgJ2359Injection, olanzapine, 0.5 mg